Therapy Persistence

Key Data:

GARFIELD-AF provides assessments on unselected population groups who are followed for a minimum of 2 years and a maximum of 8 years. Persistence with ongoing anticoagulant therapy is being evaluated using the following parameters.

  • Rate of discontinuation
  • Duration of time on therapy
  • Reasons for discontinuation

Key Publications: 

Kakkar AJ et al (2012) International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J, 163, 13-19

Global status

Read more
Total patients 57,262
Recruitment Recruitment closed
Follow-up Ongoing
Study end: 2018

Members Login

Coming soon… If you would like to be notified of when this is available click here and add your details to receive updates

Newsletter Signup






Please see our Privacy Policy and Cookie Policy

Contact Us

To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

E: garfield@tri-london.ac.uk
T: 0203 198 9947